

# Interim Report

MeVis Medical Solutions AG

H1-2020/2021



**MeVis**

# CONTENT

<b>LETTER FROM THE CEO .....</b>	<b>2</b>
<b>THE MEVIS SHARE.....</b>	<b>4</b>
<b>INTERIM MANAGEMENT REPORT H1 2020/2021 .....</b>	<b>5</b>
Preamble .....	5
Basics of the Company .....	5
Structure .....	5
Short summary of the business activities .....	5
Economic report.....	6
Business development .....	6
Earnings position .....	6
Net assets and financial position.....	7
Opportunities and risk report.....	7
Outlook .....	7
<b>BALANCE SHEET .....</b>	<b>8</b>
<b>PROFIT AND LOSS ACCOUNT .....</b>	<b>10</b>
<b>NOTES TO THE FINANCIAL STATEMENTS.....</b>	<b>11</b>
Basic information .....	11
General information .....	11
Accounting and valuation methods .....	11
Selected notes on the balance sheet and income statement.....	12
1. Receivables and other assets.....	12
2. Accruals/Provisions .....	12
3. Liabilities.....	12
4. Deferred income .....	12
5. Revenues .....	12
6. Other operating income .....	12
7. Staff costs.....	13
8. Other operating expenses .....	13
9. Relationships with related parties .....	13
Material events occurring after the balance sheet date.....	13
<b>ASSURANCE OF THE LEGAL REPRESENTATIVE .....</b>	<b>14</b>
<b>DISCLAIMER .....</b>	<b>15</b>

# LETTER FROM THE CEO

*Dear Readers,*

In the first half of the 2020/2021 financial year, the Company's revenues amounted to € 8,080 k (prev. year: € 8,677 k). The sale of licenses accounted for 30 % (prev. year: 31 %) of revenues, maintenance revenues for 35 % (prev. year: 40 %), and other revenues for 35 % (prev. year: 29 %), which include, among other things, services provided to and recharges made to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from € 2,937 k to € 2,378 k, which corresponds to an EBIT margin of 36 %, mainly as a result of lower sales, higher personnel expenses and higher other operating expenses compared with the previous year.

The change in our MeVis business structure continues. License sales are slightly down, as are maintenance sales. The decline here is mainly due to the Digital Mammography segment as a result of the changes in the cooperation with Hologic. In contrast, other revenues have gained in importance for MeVis compared to previous years. In particular, development services have developed somewhat better than expected in the last six months, mainly in joint projects with Varian Medical Systems and Varex Imaging Corporation.

Furthermore, we have continued our commitment to artificial intelligence (AI) unchanged in the first half of the year and intend to provide offerings to the market in medical but also in industrial imaging in the future. The topic and functionality of artificial intelligence will thus increasingly find its way into our product portfolio.

As in the previous fiscal year, new business with our lung cancer screening products fell short of our expectations. The positive demand for the products has not changed, but unfortunately installations of the software in hospitals have been postponed due to capacity constraints. And the general positive trend in Europe towards the adoption of lung CT screening, although still clearly visible, has come to a halt due to the Corona pandemic. We hope that the trend will pick up and continue to have a positive impact on the commercialization of our lung cancer screening products in the future.

Even more than a year after the first occurrence of infections with the SARS-CoV-2 coronavirus in Germany, we are still in an exceptional situation, even if it sometimes feels like everyday life. A large number of employees continue to work in home offices, masks are worn in the office, distance and hygiene rules are observed and regular rapid tests are carried out. There were and still are no more trade shows and events in person, at most virtually, and face-to-face visits to customers and partners became video meetings. We also had to hold our Annual General Meeting again this year as a virtual meeting, without the physical presence of shareholders and their proxies. However, we very much hope to be able to welcome our shareholders again next year at a face-to-face event. At this point in time, I expect that everyday working life as we knew it before the pandemic will change permanently and that some changes, such as more flexible working, the establishment of meetings via video conferencing and new forms of teamwork, will remain.

The impact of the Corona pandemic on the economic development of MeVis Medical Solutions AG in the current fiscal year is still difficult for us to predict at this point in time. So far, there has been no major negative impact on sales performance. However, at this point in time, we cannot rule out the possibility that this could occur in the further course of the 2020/2021 fiscal year, e.g. as a result of a decline in demand on the part of industrial customers, hospitals and clinics due to a shift in priorities for new investments.

At this point in time, we are maintaining our forecast: For the 2020/2021 financial year, a significant year-on-year decline in revenues to between € 15.0 million and € 15.5 million is expected. In addition to the expected decline in sales with the customer Hologic, sales revenues are expected to fall in the area of development services, as fewer development services will be provided compared with 2019/2020. Earnings before interest and taxes (EBIT) are expected to decline to between € 3.5 million and € 4.0 million. The forecast decline in revenues is the main driver of the decrease in EBIT, with earnings from exchange rate differences expected to break even.

As in the past reporting period, the Executive Board will regularly review its expectations in the course of fiscal 2020/2021 on the basis of current business performance.

A handwritten signature in black ink, appearing to read 'Marcus Kirchoff'. The signature is written in a cursive style with a large, sweeping flourish at the end.

Marcus Kirchoff  
CEO

## THE MEVIS SHARE

The MeVis Medical Solutions AG share showed a stable performance from October 1, 2020 to March 31, 2021. At the beginning of the fiscal year, the share was quoted at EUR 31.80 and closed at EUR 32.40 in Xetra trading at the end of March. In the course of the first half of fiscal 2020/2021, the share's high in Xetra trading was EUR 34.00 and its low was EUR 31.00. Compared to EUR 28.00 at the end of March 31, 2020, the value of the MeVis share has increased by almost 16 % in twelve months. As of March 31, 2021, the market capitalization thus amounted to approx. EUR 58 million, taking into account 1,820,000 shares in circulation.

### KEY SHARE DATA

ISIN / WKN / Ticker Symbol	DE000A0LBFE4 / A0LBFE / M3V
Industry sector	Software / Medical Technology
Subscribed capital	€ 1,820,000.00
No. of shares	1,820,000
Last quotation (XETRA) on September 30, 2020	€ 31.80
Last quotation (XETRA) on March 31, 2021	€ 32.40
Period high/low (XETRA) in 2020/2021	€ 34.00 / € 31.00
Market capitalization	€ 57.876 Mio.
General Standard (regulated market)	Frankfurt und Xetra
Over-the-counter markets	Berlin, Dusseldorf, Munich, Stuttgart
Indices	CDAX, General All-Share, DAXsector All Software

### SHAREHOLDER STRUCTURE AS AT MARCH 31, 2021

As of the balance sheet date, 73.66 % of the total share capital of MeVis Medical Solutions AG was held by Varex Imaging Deutschland AG, an indirect subsidiary of Varex Imaging Corporation, Salt Lake City, Utah, USA. Another institutional shareholder is HANSAINVEST Hanseatische Investment-GmbH with approx. 5.51 % of the total share capital of MeVis Medical Solutions AG according to the shareholder notifications we received. This means that around 20.83 % of the shares are currently in free float.

### COMPENSATION PAYMENT

The domination and profit and loss transfer agreement between Varex Imaging Deutschland AG and MMS AG obliges Varex Imaging Deutschland AG to pay a recurring cash payment ("compensation payment") to the outside shareholders for each full financial year for the duration of this agreement. This amounts to 1.13 EUR (gross) or 0.95 EUR (net) per share for each full financial year.

# INTERIM MANAGEMENT REPORT H1 2020/2021

## PREAMBLE

This report covers the first half of the 2020/2021 financial year, i.e. the period under review from October 1, 2020 to March 31, 2021. The prior-year figures given below refer to the first half of the 2019/2020 financial year from October 1, 2019 to March 31, 2020. MeVis Medical Solutions AG has prepared its annual financial statements for the 2019/2020 financial year in accordance with the provisions of the German Commercial Code applicable to corporations as well as in compliance with the German Stock Corporation Act. This interim financial statements have also been prepared on this basis.

## BASICS OF THE COMPANY

### STRUCTURE

MeVis Medical Solutions AG (hereinafter also referred to as "MMS AG", "MeVis" or the "Company") was founded in 1997 and commenced business in 1998. 73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. There is a domination and profit and loss transfer agreement in place between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Therefore MMS AG is part of the Varex Group through Varex Imaging Deutschland AG under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

Varex Imaging Corporation prepares the consolidated financial statements for the largest and smallest group of entities and MMS AG is included in these. The consolidated financial statements are filed with the U.S. Securities and Exchange Commission (SEC) and can be obtained from the head office of the group parent company.

Through a joint venture with Siemens Healthcare GmbH, Munich (hereafter: "Siemens"), MMS AG holds 51 % of MeVis BreastCare GmbH & Co. KG, Bremen, (hereafter: "MBC" or "MBC KG").

### SHORT SUMMARY OF THE BUSINESS ACTIVITIES

MMS AG develops innovative software for analyzing and evaluating image data and sells it to equipment manufacturers of medical devices and providers of medical IT platforms.

Clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases such as breast, lung, liver and neurological disorders. The software applications support many of the imaging modalities available. These not only include X-ray modalities such as computed tomography, digital mammography or digital tomosynthesis, but also magnetic resonance imaging, digital sonography and the simultaneous use of multiple modalities (multimodality). MeVis supplies technologies and software applications for global medical industry leaders, meeting their needs and helping them to strengthen their technological leadership positions.

In addition to the sale of software licenses and related maintenance contracts, MeVis offers services in the field of software programming for medical technology companies (development services). These comprise the provision of software development teams, i.e. software developers, product and project managers, application specialists and test engineers. The teams support external customers in the development of software modules or applications and in the integration of new functions and new technologies, such as algorithms based on artificial intelligence. Likewise, services are provided to clinical end customers. These include three-dimensional technical visualizations ("MeVis Distant Services"), interactive online training to improve the diagnostic skills of clinicians and internet-based special applications in teleradiology ("MeVis Online Services").

Whereas in the early years of MeVis the focus was on image-based early detection and diagnosis of breast cancer, today MeVis uses its clinical expertise, know-how from the field of breast cancer, innovative technologies as well as its partner network to successively further develop its software solutions for use in other oncological diseases.

## ECONOMIC REPORT

### BUSINESS DEVELOPMENT

The Company's operating activities consist of the development and sale of software licenses, the associated maintenance business, software programming for medical technology companies (development services) and the provision of services for technical visualizations (distant services) as well as online training.

With around 90 % (prev. year: 91 %) of total sales, the software business, which includes products for the medical technology companies Hologic, Vital Images and Invivo, again accounted for the majority of the Company's total sales in this reporting period.

The first half of the 2020/2021 financial year was again successful for MeVis in terms of its key financial indicators. The Company continued to benefit from Hologic's very good market position in breast cancer screening.

### EARNINGS POSITION

In the first half-year, the Company's revenues amounted to € 8,080 k (prev. year: € 8,677 k). 30 % (prev. year: 31 %) of the revenues are attributable to the sale of licenses, 35 % (prev. year: 40 %) to maintenance revenues and 35 % (prev. year: 29 %) to other revenues, which include, among other things, services for and oncharges to affiliated companies and the parent company. The year-on-year decrease in license revenue is mainly due to a reduction in licenses sold to the customer Hologic. The slight decrease in maintenance revenue is mainly due to a decrease in maintenance revenue from the customer Hologic due to a decrease in new maintenance contracts. The year-on-year improvement in other revenue is due to an increase in revenue from development services.

Other operating income amounted to € 781 k in the first half-year (prev. year € 415 k). This is mainly composed of income from exchange rate differences amounting to € 660 k (prev. year: € 318 k).

The cost of materials decreased to € 98 k (prev. year: € 361 k) because, in contrast to the previous year, hardly any external services were used in the lung product area (prev. year: € 258 k).

The company's staff costs amounted to € 4,351 k in the first half year (prev. year: € 4,304 k). In the year under review, the average number of permanent employees of the company was decreased by 4 to 104. The increase in staff costs is therefore primarily due to an average salary increase of approximately 3 %.

Other operating expenses amounted to € 1,970 k in the reporting period (prev. year: € 1,396 k). They comprise expenses from exchange rate differences of € 724 k (prev. year: € 339 k), rental expenses of € 267 k (prev. year: € 268 k), expenses for legal, consulting and auditing services of € 443 k (prev. year: € 233 k), sales expenses of € 21 k (prev. year: € 96 k), operating expenses of € 54 k (prev. year: € 64 k) and other operating expenses of € 460 k (prev. year: € 397 k).

Earnings before interest and taxes (EBIT) fell from € 2,937 k to € 2,378 k, mainly as a result of lower sales, higher personnel expenses and higher other operating expenses compared with the previous year.

Income from loans of financial assets amounted to € 80 k (prev. year: € 90 k) and relates to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,458 k (prev. year: € 3,022 k).

In the past half-year, income taxes of € 42 k (prev. year: € 42 k) were incurred. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG of € 2,416 k (prev. year: € 2,980 k), the net profit for the year amounts to € 0 k (prev. year: € 0 k). It should be noted that the expense from the profit and loss transfer does not legally arise until the end of the financial year.

## NET ASSETS AND FINANCIAL POSITION

The balance sheet total decreased to € 24,386 k (Sept. 30, 2020: € 27,791 k). In terms of assets, non-current assets decreased by € 35 k and current assets decreased by € 3,370 k. Equity remained constant. Accruals decreased by € 317 k and liabilities decreased by € 3,357 k. Deferred income increased by € 269 k.

The equity ratio increased to 73 % (Sept. 30, 2020: 64 %) due to the lower balance sheet total and the constant equity, while the gearing ratio fell accordingly to 27 % (Sept. 30, 2020: 36 %).

Current assets decreased by € 3,370 k to € 7,638 k as of the balance sheet date (Sept. 30, 2020: € 11,008 k). This is due, on the one hand, to the reduction of receivables from affiliated companies by € 2,454 k due to lower trade receivables from Varex Imaging Corporation and, on the other hand, to the reduction of trade receivables by € 894 k.

The Company's equity remained constant at € 17,826 k (Sept. 30, 2020: € 17,826 k) and, in addition to the subscribed capital of € 1,820 k (Sept. 30, 2020: € 1,820 k), consists of the capital reserve of € 11.461 k (Sept. 30, 2020: € 11,461 k) as well as the statutory revenue reserves of € 5k (Sept. 30, 2020: € 5 k) and the other revenue reserves of € 4,540 k (Sept. 30, 2020: € 4,540 k).

Compared to the previous year, provisions decreased by € 317 k to € 2,137 k (Sept. 30, 2020: € 2.454 k). An amount of € 9 k was added to pension provisions. Other provisions decreased to € 1,547 k, partly due to lower personnel provisions. Liabilities have decreased by € 3,357 k to € 1,767 k, mainly due to the reduction in liabilities to shareholders as of the balance sheet date from € 3,357 k to € 2,609 k (Sept. 30, 2020: € 5,966 k). Deferred income increased by € 269 k to € 1,814 k due to higher customer prepayments for services to be rendered by the Company in the future compared to the previous year.

The Company's cash and cash equivalents (cash on hand, bank balances) increased from € 3,954 k to € 4,067 k in the first half of the year.

Overall, the net assets, financial position and results of operations developed very satisfactorily.

## OPPORTUNITIES AND RISK REPORT

Since the beginning of the financial year, there have been no significant changes with regard to the risk situation of the Company. The disclosures made in the report on opportunities and risks in the financial statements as of the end of the financial year ended September 30, 2020 therefore continue to apply.

## OUTLOOK

At this point in time, we are maintaining our forecast: For the 2020/2021 financial year, a significant year-on-year decline in revenues to between € 15.0 million and € 15.5 million is expected. In addition to the expected decline in sales with the customer Hologic, sales revenues are expected to fall in the area of development services, as fewer development services will be provided compared with 2019/2020. Earnings before interest and taxes (EBIT) are expected to decline to between € 3.5 million and € 4.0 million. The forecast decline in revenues is the main driver of the decrease in EBIT, with earnings from exchange rate differences expected to break even.

As in the previous reporting period, the Executive Board will regularly review its expectations in the further course of fiscal 2020/2021 on the basis of current business developments.

Bremen, May 27, 2021



Marcus Kirchhoff  
CEO



# BALANCE SHEET

of MeVis Medical Solutions AG, Bremen, as of March 31, 2021

<b>ASSETS (FIGURES IN €)</b>	<b>Mar. 31, 2021</b>	<b>Sept. 30, 2020</b>
<b>A. Fixed Assets</b>		
<b>I. Intangible assets</b>		
Concessions, patents, licenses, trade marks and similar rights and assets	855.61	2,425.60
<b>II. Tangible assets</b>		
Property, plant and equipment	160,682.22	194,357.83
<b>III. Financial assets</b>		
1. Shares in affiliated companies	312,042.00	312,042.00
2. Loans to affiliated companies	16,225,211.69	16,225,211.69
	<u>16,537,253.69</u>	<u>16,537,253.69</u>
	<u>16,698,791.52</u>	<u>16,734,037.12</u>
<b>B. Current Assets</b>		
<b>I. Receivables and other assets</b>		
1. Trade receivables	1,852,795.01	2,747,149.74
2. Receivables from affiliated companies	1,387,665.77	3,899,106.31
3. Other assets	330,247.63	408,593.06
	<u>3,570,708.41</u>	<u>6,804,849.11</u>
<b>II. Cash in hand, credit balances with credit institutions</b>	<u>4,067,324.30</u>	<u>3,953,630.76</u>
	<u>7,638,032.71</u>	<u>11,008,479.87</u>
<b>C. Deferred income</b>	<u>49,542.27</u>	<u>48,328.36</u>
	<u>24,386,366.50</u>	<u>27,790,845.35</u>

<b>EQUITY AND LIABILITIES (FIGURES IN €)</b>	<b>Mar. 31, 2021</b>	<b>Sept. 30, 2020</b>
<b>A. Equity</b>		
<b>I. Subscribed capital</b>		
Subscribed capital	1,820,000.00	1,820,000.00
<b>II. Capital reserve</b>	11,461,332.48	11,461,332.48
<b>III. Revenue reserve</b>		
1. Legal reserve	5,000.00	5,000.00
2. Other revenue reserve	4,539,688.30	4,539,688.30
	<u>4,544,688.30</u>	<u>4,544,688.30</u>
	<u>17,826,020.78</u>	<u>17,826,020.78</u>
<b>B. Accruals/Provisions</b>		
1. Accruals for pensions	378,987.00	369,850.00
2. Tax accruals	211,844.75	170,000.00
3. Other accruals	1,546,518.74	1,914,186.15
	<u>2,137,350.49</u>	<u>2,454,036.15</u>
<b>C. Liabilities</b>		
1. Payments received on account of orders	27,581.46	21,140.51
2. Trade payables	21,536.73	92,744.29
3. Payable to affiliated companies	2,415,649.62	5,703,907.05
4. Other liabilities	144,554.98	148,464.60
	<u>2,609,322.79</u>	<u>5,966,256.45</u>
<b>D. Deferred income</b>	<u>1,813,672.44</u>	<u>1,544,531.97</u>
	<u>24,386,366.50</u>	<u>27,790,845.35</u>

## PROFIT AND LOSS ACCOUNT

of MeVis Medical Solutions AG, Bremen, for the period October 1, 2020 through March 31, 2021

FIGURES IN €	2019/2020	2019/2020
1. Revenues	8,080,155.93	8,677,059.64
2. Other operating income	781,247.61	415,087.59
3. Cost of material		
a) Cost of purchased goods	0.00	31,088.94
b) Cost of purchased services	97,947.83	329,613.33
	97,947.83	360,702.27
4. Staff cost		
a) Wages and salaries	3,663,673.42	3,578,382.68
b) Social security and pension expenses	687,150.62	726,051.44
	4,350,824.04	4,304,434.12
5. Depreciation and amortization on intangible fixed assets and tangible assets	63,818.86	93,702.00
6. Other operating expenses	1,970,483.15	1,396,293.61
7. Other interest and similar income	79,873.96	89,850.21
8. Interest and similar expenses	54.00	5,000.00
9. Taxes on income	42,500.00	42,000.00
10. Net income after tax	2,415,649.62	2,979,865.44
11. Profit to be transferred on the basis of a profit transfer agreement	2,415,649.62	2,979,865.44
12. Net income / net loss	0.00	0.00

# NOTES TO THE FINANCIAL STATEMENTS

of the half-year financial report of MeVis Medical Solutions AG, Bremen,  
as of March 31, 2021

## BASIC INFORMATION

### GENERAL INFORMATION

The registered office of the Company is in Bremen, Germany. The Company address is: Caroline-Herschel-Strasse 1, 28359 Bremen, Germany. MMS AG is entered in the Commercial Register at Bremen Local Court (HRB 23791 HB).

73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. There is a domination and profit and loss transfer agreement between Varex Imaging Deutschland AG as the controlling company and MeVis Medical Solutions AG as the controlled company. As a result, MMS AG belongs to the Varex Group via Varex Imaging Deutschland AG under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MeVis Medical Solutions AG has prepared its annual financial statements for financial year 2019/2020 in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and the German Stock Corporation Act (AktG). These interim financial statements have also been prepared on this basis. These interim financial statements were neither reviewed nor audited in accordance with Section 317 of the German Commercial Code.

### ACCOUNTING AND VALUATION METHODS

In preparing the interim financial statements and determining the comparative figures for the previous year, the same accounting policies were applied as in the 2019/2020 annual financial statements. A detailed description of these methods is published in the notes to the annual financial statements 2019/2020.

## SELECTED NOTES ON THE BALANCE SHEET AND INCOME STATEMENT

### 1. RECEIVABLES AND OTHER ASSETS

All receivables have a remaining term of up to one year.

Trade receivables amounted to € 1,853 k (Sept. 30, 2020: € 2,747 k) as of the balance sheet date and relate primarily to receivables from the customers Hologic, Vital Images and Invivo.

Receivables from affiliated companies include € 18 k (Sept. 30, 2020: € 160 k) in trade receivables from MBC KG and € 1,370 k (Sept. 30, 2020: € 3,739 k) in trade receivables from Varex Imaging Deutschland AG and Varex Imaging Corporation. In addition, receivables from affiliated companies include short-term interest receivables of € 80 k (Sept. 30, 2020: € 0 k) from a loan granted to Varex Imaging Deutschland AG.

Other assets amounted to € 330 k (Sept. 30, 2020: € 409 k) as of the balance sheet date. These mainly relate to a rent deposit of € 250 k and receivables from a grant project of € 73 k (Sept. 30, 2020: € 125 k).

### 2. ACCRUALS/PROVISIONS

Other provisions amount to € 1,547 k (Sept. 30, 2020: € 1,914 k). Of these, € 695 k (Sept. 30, 2020: € 595 k) mainly relate to outstanding invoices, € 252 k (Sept. 30, 2020: € 276 k) to provisions for vacation and overtime, € 216 k (Sept. 30, 2020: € 432 k) to provisions for bonuses, € 175 k (Sept. 30, 2020: € 385 k) to provisions for the 13th salary and € 152 k (Sept. 30, 2020: € 152 k) to provisions for guarantees.

### 3. LIABILITIES

In the reporting period, trade payables decreased by € 71 k and amounted to € 22 k at the balance sheet date. Liabilities to affiliated companies of € 2,416 k (Sept. 30, 2020: € 5,704 k) relate to the profit transfer under the existing control and profit transfer agreement with Varex Imaging Deutschland AG. The liability will legally only arise at the end of financial year 2020/2021.

### 4. DEFERRED INCOME

This item includes deferred revenue components from multi-component contracts that have already been paid but not realized. In addition, payments received from maintenance contracts are deferred if the corresponding maintenance service has not yet been performed.

### 5. REVENUES

The revenues are divided into the following revenue types:

FIGURES IN € k	Oct. 1, 2020 - Mar. 31, 2021	Oct. 1, 2019 - Mar. 31, 2020
Maintenance (software service contracts)	2,862	3,441
Services (consulting and training)	2,819	2,543
Software and licenses	2,399	2,693
	<b>8,080</b>	<b>8,677</b>

### 6. OTHER OPERATING INCOME

Other operating income in the first half-year amounted to € 781 k (prev. year: € 415 k). Of this amount, € 660 k (prev. year: € 318 k) is mainly attributable to exchange rate differences. The exchange rate differences are due to the fact that the majority of services are invoiced in US dollars and that liquidity is also held in US dollars. Due to the fact that the Company belongs to the Varex Imaging Group and in line with its corporate policy, no exchange rate hedging transactions are concluded.

## 7. STAFF COSTS

The average number of employees was 104 (prev. year: 108). This corresponds to an average of 95 full-time equivalents (prev. year: 95).

## 8. OTHER OPERATING EXPENSES

Other operating expenses in the first half of the year amounted to € 1,970 k (prev. year: € 1,396 k). These are mainly attributable to expenses from exchange rate differences of € 724 k (prev. year: € 339 k), rental expenses of € 267 k (prev. year: € 268 k) and legal, consulting and auditing costs of € 443 k (prev. year: € 233 k)

## 9. RELATIONSHIPS WITH RELATED PARTIES

The Company carries out transactions with related parties, which are explained below. These are part of the ordinary business activity and are handled as if they were with third parties.

Related parties include the jointly managed companies MBC KG and MBC GmbH, Varex Imaging Deutschland AG and, through these companies, the affiliated companies of the Varex Group, as well as the Executive Board and the Supervisory Board and their close relatives.

The following receivables, liabilities, expenses and income of the Company relate to related parties:

FIGURES IN € K	2020/2021
<b>Parent company</b>	
Receivables (from granting of loans)	16,305
Receivables (from services)	79
Liabilities (from profit transfer agreement)	2,416
Income (mainly services and interest income)	448
Expenses (from profit transfer agreement)	2,416
<b>Other affiliated companies</b>	
Receivables (from services)	1,229
Income (mainly services and interest income)	1,350

## MATERIAL EVENTS OCCURRING AFTER THE BALANCE SHEET DATE

There were no business transactions of particular significance for the Company after the balance sheet date.

## ASSURANCE OF THE LEGAL REPRESENTATIVE

"To the best of my knowledge, and in accordance with the applicable reporting principles for half-yearly financial reporting, the interim financial statements of MeVis Medical Solutions AG give a true and fair view of the assets, liabilities, financial position and profit or loss of the MeVis Medical Solutions AG and the interim management report includes a fair review of the development and performance of the business and the position of MeVis Medical Solutions AG, together with a description of the principal opportunities and risks associated with the expected development of MeVis Medical Solutions AG for the remaining months of the financial year."

Bremen, May 27, 2021

MeVis Medical Solutions AG

A handwritten signature in black ink, appearing to read "Marcus Kirchhoff". The signature is written in a cursive style with a large, stylized 'K'.

Marcus Kirchhoff

CEO

# DISCLAIMER

## FORWARD-LOOKING STATEMENT

This report contains forward-looking statements which are based on management's current estimates of future developments. Such statements are subject to risks and uncertainties, which MeVis Medical Solutions AG is not able to control or estimate with any precision, e.g. future market conditions and the general economic environment, the behavior of other market participants, the successful integration of new acquisitions and government acts. If any of these uncertainties or imponderabilities materialize or if the assumptions on which these statements are based prove to be incorrect, this may cause actual results to deviate materially from those expressly or implicitly contained in these statements. MeVis Medical Solutions AG does not intend and is under no obligation to update the forward-looking statements in the light of any events or developments occurring after the date of this report.

## DEVIATIONS FOR TECHNICAL REASONS

Deviations may occur between the accounting data contained in this report and that submitted to the Bundesanzeiger for technical reasons (e.g. conversion of electronic formats). In the case of any doubt, the version submitted to the Bundesanzeiger will prevail.

This report is also available in a German-language version. In case of any doubt, the German-language version takes priority over the English-language one.

The report is available for downloading in the internet at:

<http://www.mevis.de/en/investor-relations/financial-reports/>



**MeVis Medical Solutions AG**

Caroline-Herschel-Str. 1  
28359 Bremen  
Germany

Phone +49 421 22495 0  
Fax +49 421 22495 999  
info@mevis.de

[www.mevis.de](http://www.mevis.de)